Gerresheimer AG (ETR:GXI)
Germany · Delayed Price · Currency is EUR | Market Cap | 939.49M -54.3% |
| Revenue (ttm) | 2.25B +11.8% |
| Net Income | 23.35M -79.6% |
| EPS | 0.68 -79.6% |
| Shares Out | 34.54M |
| PE Ratio | 40.24 |
| Forward PE | 9.91 |
| Dividend | 0.04 (0.14%) |
| Ex-Dividend Date | Jun 6, 2025 |
| Volume | 261,124 |
| Open | 27.96 |
| Previous Close | 27.90 |
| Day's Range | 27.20 - 28.32 |
| 52-Week Range | 14.83 - 64.90 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 23.37 (-14.08%) |
| Earnings Date | Jul 14, 2026 |
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery progra... [Read more]
Financial Performance
In fiscal year 2024, Gerresheimer AG's revenue was 2.04 billion, an increase of 2.28% compared to the previous year's 1.99 billion. Earnings were 109.72 million, a decrease of -5.52%.
Financial StatementsNews
Gerresheimer downgraded to Hold from Buy at Jefferies
Jefferies downgraded Gerresheimer (GRRMF) to Hold from Buy with a price target of EUR 26.80, down from EUR 34.10. The firm cites the company’s delayed results, accounting concerns, and the…
Gerresheimer downgraded to Hold from Buy at Jefferies
Jefferies downgraded Gerresheimer (GRRMF) to Hold from Buy with a price target of EUR 26.80, down from EUR 34.10. The firm cites the company’s delayed results and “persistent market overhangs”…
Gerresheimer downgraded to Hold from Buy at Jefferies
Jefferies downgraded Gerresheimer (GRRMF) to Hold from Buy with a price target of C$26.80, down from C$34.10.
Gerresheimer downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Gerresheimer (GRRMF) to Underweight from Equal Weight with a price target of EUR 19, down from EUR 23. The firm prefers device manufacturing to drug containment solutions in…
Gerresheimer rejects takeover bid from Silgan, Reuters reports
Gerresheimer (GRRMF) has rejected a takeover bid from Silgan (SLGN) and there are no longer any discussions between the two companies, Reuters reports, citing three sources familiar with the situation...
Gerresheimer rejects takeover bid from US packing firm Silgan, say sources
German medical packaging maker Gerresheimer has rejected a takeover bid from its U.S. rival Silgan , three sources familiar with the situation told Reuters.
Gerresheimer delays 2025 results release to June, stock to be removed from SDAX
Gerresheimer on Tuesday again deferred the release of 2025 financial statements to June, citing a probe into its business deals, a delay that is now set to cost the German medical products maker ...
Gerresheimer downgraded to Sell from Neutral at UBS
UBS downgraded Gerresheimer (GRRMF) to Sell from Neutral with a price target of EUR 12.90, down from EUR 29. The firm is cutting estimates for the short- and mid-term to…
Gerresheimer downgraded to Underperform from Neutral at BNPP
BNPP downgraded Gerresheimer (GRRMF) to Underperform from Neutral with a EUR 22 price target
Gerresheimer AG Slides: Investor Presentation
Gerresheimer AG has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2025.
Gerresheimer price target lowered to EUR 30 from EUR 55 at Berenberg
Berenberg analyst Christian Ehmann lowered the firm’s price target on Gerresheimer (GRRMF) to EUR 30 from EUR 55 and keeps a Hold rating on the shares.
Gerresheimer appoints Uwe Röhrhoff as new interim CEO
Medical equipment maker Gerresheimer said on Tuesday it had appointed Uwe Röhrhoff as interim CEO, effective November 1, 2025. He succeeds Dietmar Siemssen, who will step down as CEO by mutual agreeme...
Gerresheimer finds 2024 revenue-recognition issues after external probe
Medical equipment maker Gerresheimer said it has obtained the initial findings from an investigation by an external law firm into the recognition of revenue and profit from bill-and-hold agreements in...
Gerresheimer downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Gerresheimer (GRRMF) to Equal Weight from Overweight with a price target of EUR 23, down from EUR 64. The firm says visibility into the investment case is low…
Gerresheimer price target lowered to EUR 46 from EUR 99.30 at JPMorgan
JPMorgan lowered the firm’s price target on Gerresheimer (GRRMF) to EUR 46 from EUR 99.30 and keeps an Overweight rating on the shares.
Gerresheimer downgraded to Neutral from Buy at UBS
UBS analyst Olivier Calvet downgraded Gerresheimer (GRRMF) to Neutral from Buy with a price target of EUR 29, down from EUR 75. The firm sees uncertainties following the company’s third…
Gerresheimer price target lowered to EUR 34 from EUR 49 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Gerresheimer (GRRMF) to EUR 34 from EUR 49 and keeps a Hold rating on the shares. Published first on…
Gerresheimer downgraded to Sell from Hold at DZ Bank
DZ Bank downgraded Gerresheimer (GRRMF) to Sell from Hold with a EUR 25 price target
Gerresheimer AG Earnings Call Transcript: Q3 2025
Q3 and nine-month results were below expectations, with organic revenue and EBITDA declines driven by weak cosmetics and oral liquids markets. Guidance was revised downward, a transformation program was launched, and liquidity remains strong with no covenant breaches.
Gerresheimer AG Quarterly report: Q3 2025
Gerresheimer AG has published its Q3 2025 quarterly earnings report on October 10, 2025.
Gerresheimer AG Slides: Q3 2025
Gerresheimer AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 10, 2025.
Gerresheimer's shares fall 11% after another outlook cut
Shares in Gerresheimer fell 11% on Thursday, a day after the German packaging and medical equipment maker cut its 2025 guidance for the third time this year.
Gerresheimer AG Earnings Call Transcript: Q3 2025
Q3 and the first nine months of 2025 were below expectations, with organic revenue and EBITDA both declining year-over-year. Guidance was revised downward, with a projected organic revenue decline of -4% to -2% and an adjusted EBITDA margin of 18.5%-19%.
Gerresheimer AG Earnings release: Q3 2025
Gerresheimer AG released its Q3 2025 earnings on October 9, 2025, summarizing the period's financial results.
Gerresheimer AG Slides: Q3 2025
Gerresheimer AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 9, 2025.